2024 年第 8 期 第 0 卷

马来酸阿法替尼片联合顺铂加紫杉醇治疗晚期非小细胞肺癌的效果研究

Study on the effect of afatinib maleate tablets combined with cisplatin and paclitaxel in the treatment of advanced non-small cell lung cancer

作者：牛素梅1张驰1马燕1许斌2段文婷1钱智磊1

英文作者：Niu Sumei1 Zhang Chi1 Ma Yan1 Xu Bin2 Duan Wenting1 Qian Zhilei1

单位：1南京医科大学附属脑科医院/胸科医院药学部，南京210029；2南京医科大学附属脑科医院/胸科医院呼吸科，南京210029

英文单位：1Department of Pharmacy the Affiliated Brain Hospital/Chest Hospital of Nanjing Medical University Nanjing 210029 China; 2Department of Respiratory the Affiliated Brain Hospital/Chest Hospital of Nanjing Medical University Nanjing 210029 China

关键词：非小细胞肺癌；阿法替尼；顺铂；紫杉醇

英文关键词：Non-smallcelllungcancer;Afatinib;Cisplatin;Paclitaxel

• 摘要：

• 目的 探讨马来酸阿法替尼片联合顺铂加紫杉醇治疗晚期非小细胞肺癌的效果。方法 收集2019年1月至2022年9月南京医科大学附属脑科医院/胸科医院收治的80例晚期非小细胞肺癌患者的临床资料行回顾性分析。按照治疗方法不同分为对照组和观察组，各40例。对照组采用顺铂加紫杉醇的化疗方案进行治疗，观察组在对照组的基础上联用马来酸阿法替尼片进行治疗。比较2组的疗效、肿瘤标志物水平、中国癌症患者化学生物治疗生活质量量表（QLQ-CCC）评分、不良反应发生情况及12个月生存率。结果 观察组疾病控制率高于对照组［82.5%（33/40）比62.5%（25/40）］，差异有统计学意义（χ2=4.013，P=0.045）；2组客观缓解率比较差异无统计学意义（χ2=0.503，P=0.478）。治疗后2组糖类抗原125、细胞角蛋白19片段及癌胚抗原水平均低于治疗前且观察组均低于对照组，差异均有统计学意义（均P<0.05）。治疗后2组QLQ-CCC总体感觉、心理功能、社会功能、躯体功能评分均高于治疗前且观察组均高于对照组，差异均有统计学意义（均P<0.05）。2组不良反应发生率比较差异无统计学意义（χ2=0.879，P=0.348）。观察组的12个月生存率高于对照组［62.5%（25/40）比40.0%（16/40）］，差异有统计学意义（χ2=4.053，P=0.044）。结论 马来酸阿法替尼片联合顺铂加紫杉醇治疗晚期非小细胞肺癌可获得较好的效果，疾病控制率能达到较高水准，并能有效降低肿瘤标志物水平、改善患者的生活质量、提升短期生存率。

• Objective To explore the effect of afatinib maleate tablets combined with cisplatin and paclitaxel in the treatment of advanced non-small cell lung cancer. Methods  The clinical data of 80 patients with advanced non-small cell lung cancer admitted to the Affiliated Brain Hospital/Chest Hospital of Nanjing Medical University from January 2019 to September 2022 were retrospectively analyzed. According to different treatment methods, they were divided into control group and observation group, with 40 cases in each group. The control group was treated with cisplatin and paclitaxel chemotherapy, and the observation group was treated with afatinib maleate tablets on the basis of the control group. The efficacy, tumor marker level, the quality of life questionnaire-Chinese cancer chemotherapy patients(QLQ-CCC) score, incidence of adverse reactions, and 12-month survival rate were compared between the two groups. Results  The disease control rate in the observation group was higher than that in the control group［82.5%(33/40) vs 62.5%(25/40)］(χ2=4.013, P=0.045). There was no statistically significant difference in objective response rate between the two groups(χ2=0.503, P=0.478). After treatment, the average levels of carbohydrate antigen 125, cytokeratin 19 fragment, and carcinoembryonic antigen in the two groups were lower than before treatment, and those in the observation group were lower than those in the control group(all P<0.05). After treatment, the scores of general feeling, psychological function, social function and physical function of QLQ-CCC in both groups were higher than those before treatment, and those in the observation group were higher than those in the control group (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(χ2=0.879, P=0.348). The 12-month survival rate of the observation group was higher than that of the control group［62.5%(25/40) vs 40.0%(16/40)］(χ2=4.053，P=0.044). Conclusion  Afatinib maleate tablets combined with cisplatin and paclitaxel in the treatment of advanced non-small cell lung cancer can achieve a good effect, the disease control rate can reach a high level, and can effectively reduce the level of tumor markers, improve the quality of life of patients, and improve the short-term survival rate.